Systematic identification of pathological mechanisms, prognostic biomarkers and therapeutic targets by integrating lncRNA expression variation in salivary gland mucoepidermoid carcinoma
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.This study reveals that epithelial-mesenchymal transition (EMT) is key in mucoepidermoid carcinoma (MEC) development, linking high EMT scores to poor prognosis and active immune responses. It identifies potential therapeutic targets for MEC treatment.
Area Of Science
- Oncology
- Molecular Biology
- Immunology
Background
- Biological processes significantly impact cancer development, treatment, and prognosis.
- The specific mechanisms driving mucoepidermoid carcinoma (MEC) tumorigenesis require further investigation.
Purpose Of The Study
- To explore the biological mechanisms and immune microenvironment characteristics of MEC tumorigenesis.
- To identify key pathways and molecular mediators involved in MEC development.
- To assess the prognostic value of epithelial-mesenchymal transition (EMT) and immune signatures in MEC.
Main Methods
- Analysis of lncRNA expression profiles from clinical MEC and normal tissues.
- Integration of public expression data.
- Gene set enrichment analysis (GSEA) to identify key pathways.
- Calculation of a customized EMT score and immune signature analysis.
Main Results
- Significant enrichment of the EMT pathway in MEC, with Secretogranin II, tissue factor pathway inhibitor 2, and periostin identified as key contributors.
- High EMT scores correlated with upregulated EMT and immune response, indicating a poor prognosis.
- Immune signature analysis revealed active antigen presentation and potential for immunotherapy response.
- SLC2A1-AS1 and CERS6-AS1 were identified as potential mediators of EMT and the tumor immune environment.
Conclusions
- Epithelial-mesenchymal transition (EMT) plays a critical role in mucoepidermoid carcinoma (MEC) tumorigenesis and prognosis.
- The tumor immune microenvironment in MEC suggests potential for immunotherapy.
- SLC2A1-AS1 and CERS6-AS1 represent potential therapeutic targets for MEC.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...